Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7862]

Drug modifies epigenome in aggressive brain tumours

Drug modifies epigenome in aggressive brain tumours

Aberrant splicing of CD22 in acute lymphoblastic leukaemia underlies resistance to immunotherapy

Aberrant splicing of CD22 in acute lymphoblastic leukaemia underlies resistance to immunotherapy

CBD reduces glioblastoma’s size, supportive environment in experimental model

CBD reduces glioblastoma’s size, supportive environment in experimental model

Phase I/II study shows increased PFS for patients with r/r multiple myeloma who received ixazomib in combination with pomalidomide and dexamethasone

Phase I/II study shows increased PFS for patients with r/r multiple myeloma who received ixazomib in combination...

Analysis tool leads to more-accurate evaluation of new brain tumour treatments and individual estimates of survival

Analysis tool leads to more-accurate evaluation of new brain tumour treatments and individual estimates of survival

Research breakthrough could see HIV drugs used to treat low-grade brain tumours

Research breakthrough could see HIV drugs used to treat low-grade brain tumours

Researchers zero in on therapeutic target for aggressive uterine cancer

Researchers zero in on therapeutic target for aggressive uterine cancer

Lung cancer death decline associated with screening, earlier diagnosis, and surgery

Lung cancer death decline associated with screening, earlier diagnosis, and surgery

Prostate cancer medicine not a cure for COVID-19

Prostate cancer medicine not a cure for COVID-19

Amivantamab, the first treatment approved for patients with advanced NSCLC with EGFR exon 20 insertion mutations after failure of platinum-based therapy

Amivantamab, the first treatment approved for patients with advanced NSCLC with EGFR exon 20 insertion mutations...

More from ecancer